The amino terminus of JAK3 is necessary and sufficient for binding to the common γ chain and confers the ability to transmit interleukin 2-mediated signals
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
JAK3 is a protein tyrosine kinase that specifically associates with the common γ chain (γ c), a shared subunit of receptors for interleukin (IL) 2, 4, 7, 9, and 15. Patients deficient in either JAK3 or γ c presented with virtually identical forms of severe combined immunodeficiency (SCID), underscoring the importance of the JAK3–γ c interaction. Despite the key roles of JAK3 and γ c in lymphocytic development and function, the molecular basis of this interaction remains poorly understood. In this study, we have characterized the regions of JAK3 involved in γ c association. By developing a number of chimeric JAK3–JAK2 constructs, we show that the binding specificity to γ c can be conferred to JAK2 by transferring the N-terminal domains of JAK3. Moreover, those JAK3–JAK2 chimeras capable of binding γ c were also capable of reconstituting IL-2 signaling as measured by inducible phosphorylation of the chimeric JAK3–JAK2 protein, JAK1, the IL-2 receptor β chain, and signal transducer and activator of transcription 5A. Subsequent deletion analyses of JAK3 have identified the N-terminal JH7-6 domains as a minimal region sufficient for γ c association. Furthermore, expression of the mutant containing only the JH7-6 domains effectively competed with full-length JAK3 for binding to γ c. We conclude that the JH7-6 domains of JAK3 are necessary and sufficient for γ c association. These studies offer clues toward a broader understanding of JAK-mediated cytokine signaling and may provide a target for the development of novel therapeutic modalities in immunologically mediated diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway
Schindler, C., & Darnell, J. E. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003201 · Cited by 1,808
Association and Activation of Jak-Tyk Kinases by CNTF-LIF-OSM-IL-6 β Receptor Components
Stahl, N., Boulton, T. G., Farruggella, T., Ip, N. Y., Davis, S., Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Barbieri, G., Pellegrini, S., et al. (1994) · Science · doi:10.1126/science.8272873 · Cited by 979
Lin, J.-X., Migone, T.-S., Tseng, M., Friedmann, M., Weatherbee, J. A., Zhou, L., Yamauchi, A., Bloom, E. T., Mietz, J., John, S., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90141-8 · Cited by 752
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I
Migone, T.-S., Lin, J.-X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., & Leonard, W. J. (1995) · Science · doi:10.1126/science.7604283 · Cited by 557
Self-citationJak-STAT Signaling Induced by the v- abl oncogene
Danial, N. N., Pernis, A., & Rothman, P. B. (1995) · Science · doi:10.1126/science.7569929 · Cited by 325
Cited by
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
JAKS AND STATS: Biological Implications
Leonard, W. J., & O'Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,804
Self-citationSignaling through the JAK/STAT pathway, recent advances and future challenges
Kisseleva, T., Bhattacharya, S., Braunstein, J., & Schindler, C. W. (2002) · Gene · doi:10.1016/s0378-1119(02)00398-0 · Cited by 1,154
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
“Chimeric constructs containing the aminoterminal domain of Jak3 or mutated Jak3 proteins containing only the FERM domains effectively bind the common c (cc) chain (21).”
BackgroundSelf-citationWieckowski, E. U., Visus, C., Szajnik, M., Szczepanski, M. J., Storkus, W. J., & Whiteside, T. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900970 · Cited by 560
Biology of the Interleukin-2 Receptor
Nelson, B. H., & Willerford, D. M. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60386-7 · Cited by 475
Janus kinases: components of multiple signaling pathways
Rane, S. G., & Reddy, E. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203925 · Cited by 466
Janus kinase inhibitors in autoimmune diseases
O'Shea, J. J., Kontzias, A., Yamaoka, K., Tanaka, Y., & Laurence, A. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202576 · Cited by 453
Self-citationNicholson, S. E., Willson, T. A., Farley, A., Starr, R., Zhang, J., Baca, M., Alexander, W. S., Metcalf, D., Hilton, D. J., & Nicola, N. A. (1999) · The EMBO Journal · doi:10.1093/emboj/18.2.375 · Cited by 407
Jaks, STATs, Cytokine Signal Transduction, and Immunoregulation: Are We There Yet?
O'Shea, J. J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80505-1 · Cited by 386
Self-citationKovanen, P. E., & Leonard, W. J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00203.x · Cited by 360
Flanagan, M. E., Blumenkopf, T. A., Brissette, W. H., Brown, M. F., Casavant, J. M., Shang-Poa, C., Doty, J. L., Elliott, E. A., Fisher, M. B., Hines, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1004286 · Cited by 334
Self-citationCytokine receptor signaling through the Jak–Stat–Socs pathway in disease
O'Sullivan, L. A., Liongue, C., Lewis, R. S., Stephenson, S. E. M., & Ward, A. C. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.11.025 · Cited by 308
Dehkhoda, F., Lee, C. M. M., Medina, J., & Brooks, A. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00035 · Cited by 304
Functional Association of Nmi with Stat5 and Stat1 in IL-2- and IFN γ-Mediated Signaling
Zhu, M.-H., John, S., Berg, M., & Leonard, W. J. (1999) · Cell · doi:10.1016/s0092-8674(00)80965-4 · Cited by 303
Levine, R. L., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2008-03-077966 · Cited by 279
The Jak-Stat Pathway: Cytokine Signalling from the Receptor to the Nucleus
Heim, M. H. (1999) · Journal of Receptors and Signal Transduction · doi:10.3109/10799899909036638 · Cited by 271
JAKs, STATs and Src kinases in hematopoiesis
Rane, S. G., & Reddy, E. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205398 · Cited by 242
“…plausible that these domains facilitate some key functions like protein ± protein interactions, recruitment of substrates, etc. Consistent with this hypothesis, recent studies indicate that the amino terminal regions may be involved in receptor binding (Chen et al., 1997; Gauzzi et al., 1997).”
Therapeutic targeting of Janus kinases
Pesu, M., Laurence, A., Kishore, N., Zwillich, S. H., Chan, G., & O'Shea, J. J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00644.x · Cited by 231
Self-citationSarapultsev, A., Gusev, E., Komelkova, M., Utepova, I., Luo, S., & Hu, D. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00151-1 · Cited by 221
Blalock, W., Weinstein-Oppenheimer, C., Chang, F., Hoyle, P., Wang, X.-Y., Algate, P., Franklin, R., Oberhaus, S., Steelman, L., & McCubrey, J. (1999) · Leukemia · doi:10.1038/sj.leu.2401493 · Cited by 158
The use of structural biology in Janus kinase targeted drug discovery
L. Alicea-Velazquez, N., & J. Boggon, T. (2011) · Current Drug Targets · doi:10.2174/138945011794751528 · Cited by 53
Witthuhn, B. A., Williams, M. D., Kerawalla, H., & Uckun, F. M. (1999) · Leukemia & Lymphoma · doi:10.3109/10428199909167389 · Cited by 28
Metadata
- Authors
- Chen, M., Cheng, A., Chen, Y.-Q., Hymel, A., Hanson, E. P., Kimmel, L., Minami, Y., Taniguchi, T., Changelian, P. S., & O’Shea, J. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-06-24
- Volume
- 94
- Issue
- 13
- Pages
- 6910-6915
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1964220962
- Cited by
- 145
- References
- 5
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.